Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 269

The DOI matches its Crossref record.

INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS

KAHAN, BARRY D. · 1985 · Transplantation

Abstract

Initial studies utilizing cyclosporine (CsA)1 immunosuppression documented not only therapeutic efficacy (1), but also appreciable interindividual variation, both in clinical responses and in serum drug concentrations, in spite of fixed dosage regimens (2, 3). Optimal CsA schedules are difficult to establish: on the one hand, the therapeutic effect is not easily quantitated, both because of the absence of objective signs, such as blood pressure provides for antihypertensive agents, and because of the delayed time frame in which to detect rejection in the event of inadequate therapy, which results from the lack of suitable intermediate points with proved correlation with immunosuppression. On the other hand, CsA causes toxic side effects capable of increasing morbidity. Assuming that toxic levels of CsA exceed therapeutic levels, many physicians have routinely administered enough CsA to keep the patient nephrotoxic, in order to avert rejection. However, high initial doses of CsA appear to be associated with intractable nephrotoxicity and renal interstitial fibrosis (4). Indeed, as in theophylline, there appears—at least in some patients—to be an overlap of the concentration/response relationship for therapeutic and toxic effects, neither of which are clearly related to the administered dose. In other pharmacologic settings of a narrow therapeutic range, in part because of the lipophilic nature of the agent and its low apparent bioavailability, with toxic side effects upon overdosage and minimal effect upon underdosage, individualization of the drug regimen has achieved the specific goals of treatment. This overview addresses the question of whether therapeutic drug monitoring, pharmacokinetic analyses, and/or pharmacodynamic assessment of renal transplant recipients proffer criteria suitable for individualization of the CsA regimen, in order to afford prophylaxis of rejection episodes and minimize nephrotoxicity, thereby improving the risk: benefit ratio, obviating the variable outcome, and achieving uniform success of immunosuppressive therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-198511000-00001

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 269

Metadata

Authors
KAHAN, B. D.
Venue
Transplantation
Published
1985-11
Volume
40
Issue
5
Pages
457-476
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2008523006
Cited by
269
References
0
FWCI
18.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. https://app.cochat.ai/papers/10.1097/00007890-198511000-00001
The paper
KAHAN, B. D. (1985). INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. Transplantation. https://doi.org/10.1097/00007890-198511000-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.